← Back to Treatments
🏅 FDA Orphan Designation

Eylea

aflibercept

Manufacturer: Regeneron Pharmaceuticals, Inc.

Indicated for:
Retinopathy of prematurityOrphanCentral retinal vein occlusionNON RARE IN EUROPE: Age-related macular degenerationCystoid macular dystrophyDiabetic embryopathy

FDA-Approved Indications (5)

Retinopathy of prematurityOrphan Designation

treatment of retinopathy of prematurity (ROP)

indicated for the treatment of patients with Macular Edema Following Retinal Vein Occlusion (RVO)

Population: patients

indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (nAMD)

Population: patients

indicated for the treatment of patients with Diabetic Macular Edema (DME)

Population: patients

indicated for the treatment of patients with Diabetic Retinopathy (DR)

Population: patients

Indications & Usage

1 INDICATIONS AND USAGE EYLEA HD is indicated for the treatment of: EYLEA HD is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (nAMD) ( 1.1 ) Diabetic Macular Edema (DME) ( 1.2 ) Diabetic Retinopathy (DR) ( 1.3 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.4 ) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (nAMD) 1.2 Diabetic Macular Edema (DME) 1.3 Diabetic Retinopathy (DR) 1.4 Macular Edema Following Retinal Vein Occlusion (RVO)

💙 Support Programs

View all →
EYLEA
Regeneron
Copay card ↗Apply ↗
Eylea
Regeneron Pharmaceuticals, Inc.
Apply ↗
EYLEA HD
Regeneron
Copay card ↗Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.